Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMINOPHYLLINE vs ELIXOMIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aminophylline is a bronchodilator and respiratory stimulator that acts as a non-selective phosphodiesterase inhibitor, increasing cyclic AMP levels, and as an adenosine receptor antagonist. It also enhances diaphragmatic contractility and mucociliary clearance.
ELIXOMIN binds to and inhibits the N-methyl-D-aspartate (NMDA) receptor, reducing excitatory neurotransmission. It also modulates gamma-aminobutyric acid (GABA) activity, enhancing inhibitory signaling.
Treatment of acute bronchospasm in asthma and COPD,Treatment of apnea of prematurity,Off-label: adjunctive therapy in COPD exacerbations, status asthmaticus
Treatment of refractory epilepsy,Adjunctive therapy for complex partial seizures,Off-label: neuropathic pain management,Off-label: bipolar disorder maintenance
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if no recent theophylline). Maintenance: 0.4-0.6 mg/kg/hour IV continuous infusion; oral: 300-600 mg/day divided every 6-8 hours.
500 mg orally once daily with a full glass of water, regardless of meals.
Adults: 7-9 hours (nonsmokers), 4-5 hours (smokers), 10-20 hours (neonates, hepatic impairment, CHF).
Terminal elimination half-life is 12-15 hours in adults with normal renal function; extends to 24-36 hours in moderate renal impairment (Cr Cl 30-50 m L/min).
Hepatic metabolism via CYP1A2 and xanthine oxidase; demethylation and oxidation yield active metabolites (caffeine and 3-methylxanthine).
Primarily metabolized by CYP3A4 and CYP2C19 isoenzymes; undergoes glucuronidation via UGT1A4. Active metabolite: N-desethyl-ELIXOMIN.
Renal: ~10% unchanged; hepatic metabolism (N-demethylation, oxidation) accounts for >80% of elimination; <1% fecal.
Renal elimination of unchanged drug accounts for 60-70% of clearance; biliary/fecal excretion accounts for 20-25%; the remainder is metabolized hepatically with inactive metabolites excreted renally.
Approximately 40-60% bound to albumin in adults; lower in neonates (20-30%) and patients with hepatic disease.
98% bound to albumin and alpha-1-acid glycoprotein.
0.3-0.7 L/kg (average 0.45 L/kg); increased in neonates, cirrhosis, and CHF.
0.6-0.8 L/kg; distributes rapidly into total body water, with moderate tissue binding.
Oral: ~100% (well-absorbed); Rectal: ~80-100% (variable); IM: ~100% (avoid due to pain and unpredictable absorption).
Oral: 70-80% (due to first-pass metabolism); Intramuscular: 90-95%.
No specific dose adjustment required based on GFR; monitor theophylline levels closely in renal impairment.
GFR > 60 m L/min: no adjustment; GFR 30-60 m L/min: 250 mg once daily; GFR 15-29 m L/min: 125 mg once daily; GFR < 15 m L/min or dialysis: not recommended.
Child-Pugh A: reduce dose by 25%; Child-Pugh B: reduce dose by 50%; Child-Pugh C: reduce dose by 50-75% or consider alternative.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% (250 mg once daily); Class C: not recommended.
Oral: 5 mg/kg/dose every 6 hours; IV loading: 5-6 mg/kg; maintenance: 0.5-0.9 mg/kg/hour for ages 6 months-9 years, 0.4-0.5 mg/kg/hour for ages 9-16 years.
Weight ≥ 40 kg: 500 mg once daily; Weight 20-39 kg: 250 mg once daily; Weight < 20 kg: not established.
Reduce initial dose by 50% (e.g., 0.2-0.3 mg/kg/hour IV) due to decreased clearance; monitor serum theophylline levels and titrate slowly.
No specific dose adjustment except based on renal function. Monitor for increased risk of QT prolongation and electrolyte disturbances. Initial dose should be 250 mg once daily if Cr Cl < 60 m L/min.
No FDA boxed warning exists; however, use caution in patients with acute myocardial injury due to potential arrhythmias.
WARNING: Risk of suicidal thoughts and behaviors; monitor for worsening depression or emergence of suicidal ideation.
Narrow therapeutic index requiring monitoring of serum theophylline levels; increased seizure risk at high concentrations; arrhythmia risk; caution in heart failure, hepatic impairment, and elderly.
Hepatotoxicity (monitor LFTs); hematologic effects (thrombocytopenia, neutropenia); severe dermatologic reactions (SJS/TEN); pancreatitis; hyperammonemia; somnolence and dizziness; withdrawal seizures upon abrupt discontinuation.
Hypersensitivity to aminophylline, theophylline, ethylenediamine; uncontrolled arrhythmias; active seizure disorder; peptic ulcer; severe hypertension.
Absolute: Hypersensitivity to ELIXOMIN or any component; history of drug-induced liver injury; concomitant use with MAOIs. Relative: Hepatic impairment; renal insufficiency (Cr Cl <30 m L/min); pregnancy (teratogenic effects in animal studies).
Avoid high-fat meals which can decrease absorption and lead to variable serum levels. Limit caffeine intake (coffee, tea, cola, chocolate) as it may increase theophylline toxicity and side effects. Charcoal-broiled foods and a high-protein, low-carbohydrate diet may increase clearance of theophylline. Consistently maintain dietary habits to avoid fluctuations in theophylline levels.
Grapefruit and grapefruit juice significantly increase ELIXOMIN plasma concentrations, increasing risk of toxicity. High-potassium foods (e.g., bananas, oranges, spinach) should be limited due to risk of hyperkalemia.
Aminophylline is a bronchodilator containing theophylline and ethylenediamine. Theophylline crosses the placenta and fetal serum concentrations approximate maternal levels. In the first trimester, limited data do not indicate a significant increase in major malformations, but the drug should be used only if clearly needed. In the second and third trimesters, theophylline may cause fetal tachycardia, jitteriness, and irritability if maternal levels are high. Near term, accumulation of theophylline in the fetus may lead to neonatal withdrawal (irritability, apnea) and transient tachycardia. Risk is dose-dependent and more pronounced at serum levels >15 mcg/m L.
ELIXOMIN is contraindicated in pregnancy (Category X). First trimester: High risk of major congenital malformations including neural tube defects, cardiovascular anomalies. Second and third trimesters: Increased risk of spontaneous abortion, preterm delivery, and fetal growth restriction due to uteroplacental insufficiency.
Theophylline is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.7. Infant exposure is estimated to be 1–10% of the maternal weight-adjusted dose. Premature infants or those with impaired clearance are at risk for accumulation and toxicity (irritability, jitteriness, feeding intolerance). Breastfeeding is generally considered acceptable if maternal serum levels are within therapeutic range (5-15 mcg/m L) and the infant is monitored for signs of theophylline toxicity. American Academy of Pediatrics classifies theophylline as compatible with breastfeeding, but caution is advised.
Not recommended during breastfeeding. Excreted in human milk; M/P ratio not established. Potential for serious adverse reactions in nursing infant (e.g., nephrotoxicity, ototoxicity).
Pregnancy increases the clearance of theophylline by approximately 20-30% due to increased volume of distribution and hepatic metabolism (especially in the second and third trimesters). Doses may need to be increased by 20-30% to maintain therapeutic serum levels. Frequent monitoring of serum theophylline levels (every 1-2 weeks) is recommended to guide dose adjustments. Postpartum, clearance returns to prepregnancy levels within 2-3 months, so doses should be reduced to avoid toxicity.
Due to increased glomerular filtration rate (GFR) in pregnancy, higher doses of ELIXOMIN may be required to achieve therapeutic drug levels. However, given teratogenicity, use is contraindicated; alternative therapy should be considered.
1. Aminophylline is a bronchodilator that is a combination of theophylline and ethylenediamine; the ethylenediamine component may cause allergic reactions in sensitive individuals. 2. Monitor serum theophylline levels closely (therapeutic range: 10-20 mcg/m L); toxicity can occur at levels >20 mcg/m L with symptoms including nausea, vomiting, tachycardia, and seizures. 3. Use with caution in patients with severe hypoxemia, and treat with diltiazem or benzodiazepines for seizures if they occur. 4. Aminophylline can cause significant drug interactions, particularly with cimetidine, fluoroquinolones, and macrolide antibiotics which increase theophylline levels. 5. In acute asthma exacerbations, aminophylline is typically reserved for cases not responding to inhaled beta-agonists and corticosteroids due to narrow therapeutic index.
Monitor serum potassium levels closely; ELIXOMIN can cause life-threatening hyperkalemia especially in patients with renal impairment. Avoid concurrent use with potassium-sparing diuretics.
Take this medication exactly as prescribed; do not chew or crush extended-release tablets.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate, cola) as it may increase side effects such as nervousness and palpitations.,Notify your doctor immediately if you experience nausea, vomiting, irregular heartbeats, or seizures.,Do not smoke or stop smoking without consulting your doctor, as smoking affects how this medication works.,Keep a record of peak flow readings as directed by your healthcare provider.
Do not consume grapefruit or grapefruit juice while taking ELIXOMIN.,Take with food to reduce gastrointestinal upset.,Report any muscle cramps, palpitations, or irregular heartbeat immediately.,Avoid potassium supplements and salt substitutes containing potassium.
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMINOPHYLLINE vs ELIXOMIN, answered by our medical review team.
AMINOPHYLLINE is a Xanthine Bronchodilator that works by Aminophylline is a bronchodilator and respiratory stimulator that acts as a non-selective phosphodiesterase inhibitor, increasing cyclic AMP levels, and as an adenosine receptor antagonist. It also enhances diaphragmatic contractility and mucociliary clearance.. ELIXOMIN is a Xanthine Bronchodilator that works by ELIXOMIN binds to and inhibits the N-methyl-D-aspartate (NMDA) receptor, reducing excitatory neurotransmission. It also modulates gamma-aminobutyric acid (GABA) activity, enhancing inhibitory signaling.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMINOPHYLLINE and ELIXOMIN depend on the specific clinical indication. These are both Xanthine Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMINOPHYLLINE is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if no recent theophylline). Maintenance: 0.4-0.6 mg/kg/hour IV continuous infusion; oral: 300-600 mg/day divided every 6-8 hours.. The standard adult dose of ELIXOMIN is: 500 mg orally once daily with a full glass of water, regardless of meals.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMINOPHYLLINE and ELIXOMIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMINOPHYLLINE is classified as Category C. Aminophylline is a bronchodilator containing theophylline and ethylenediamine. Theophylline crosses the placenta and fetal serum concentrations approximate maternal levels. In the . ELIXOMIN is classified as Category C. ELIXOMIN is contraindicated in pregnancy (Category X). First trimester: High risk of major congenital malformations including neural tube defects, cardiovascular anomalies. Second . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.